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Abstract The aim of this study was to verify the efficacy
and the safety of transtympanic dexamethasone to treat
sudden sensorineural hearing loss as first and single drug
method. Considering ethical implication of performing a
mininvasive procedure on middle ear, we matched such
proposed treatment with systemic prednisone administra-
tion that represents the widest adopted protocol. Random-
ized prospective study was conducted. The inclusion
criterion was a sudden sensorineural hearing loss of at least
30 dB across three contiguous frequencies over a period of
24 h. Group A received transtympanic steroid injections;
Group B received oral administration of steroids. 25
patients were treated with transtympanic therapy whereas
21 underwent systemic treatment. The mean of initial PTA
was 59 dB for the whole series: 65 dB for group A and
51 dB for group B. The recovery better than 10 dB was
obtained in 80% of patients of group A and in 17 81% of
patients of group B, with a total of 80.5%. The mean rel-
ative gain in PTA was 41.16% in the group A and 44.7% in
the group B. In the frequencies tested (0.5, 1, 2, and 4 kHz)
PTA improvements after transtympanic treatment were
higher than after systemic treatment, but these differences
were not statistically significant (P = 0.61). Both trans-
tympanic and systemic treatment had similar clinical
recovery times. This prospective randomized clinical study
showed good result in terms of hearing recovery, better
than the expected results of the simple observation without
treatment. We can consider transtympanic administration
as a first line treatment, because of the statistical analysis
confirmed similar results with systemic therapy, reducing
possible side effects of systemic drug administration. The
delay of treatment does not influence the outcome, allow-
ing treating patients within 10 days of onset.
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Introduction
The sudden onset of deafness characterizes several dis-
eases. In more than 90% of patients, the true cause of the
hearing loss is not discovered, constituting an idiopathic
syndrome known as Sudden Sensorineural Hearing Loss
(SSHL). The estimated incidence of such disease is 5–20
cases per 100,000 annually [1]. However, the exact inci-
dence is not known mainly due to the lack of a widely
accepted definition of the disease. The US National Insti-
tute for Deafness and Communication Disorders defines
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SSHL as the idiopathic loss of hearing of at least 30 dB
over at least three contiguous frequencies occurring within
3 days. The underestimation of the incidence is probably
because many patients who recover early (within first few
days) are unlikely to seek medical care.
The spontaneous recovery rate is approximately
between 32 and 65% which encourage some otologists not
to treat SSHL patients [2].
The high rate of spontaneous recovery is, furthermore, a
confounding element in the evaluation of the treatment
protocols. Every protocol applied should improve the
recovery rate up to 65% that could be obtained theoreti-
cally in case of simple observation.
The lack of consensus in the management of SSHL is
due to difficulty in finding the true etiology of the deafness.
Numerous treatments have been described: steroids, anti-
viral drugs, osmotic diuretics, anticoagulants, vasodilators,
hyperbaric oxygen, and carbogen; most of therapies
showed some benefits in restore hearing notwithstanding
the lack of robustness of the data.
The most widely employed drugs in management of
SSHL were steroids. Steroid were either administered as a
single agent or associated with other drugs. Several placebo-
controlled trials reported encouraging results in terms of
recovering of hearing loss [3, 4], although other authors
discussed such efficacy in the treatment of SSHL [1, 2, 5, 6].
The disadvantages of systemic treatment with steroids
are well-known long-term complications.
The knowledge of cochlear pharmacokinetic allowed
otologists to adopt ways to administer drugs into inner ear
spaces, bypassing the systemic circulation. The round
window is the main access to inner ear for the drugs
injected into middle ear cleft. This method was first used in
the management of Meniere’s disease with either Genta-
micin or steroids. The transtympanic steroid (TTS) injec-
tion is an intriguing therapeutic option in management of
SSHL. Several report in the recent years have showed some
benefits after use of TTS: Haynes et al. [7] and Ahn et al.
[8] reported improvement after use of TTS as salvage
therapy after systemic steroid treatment failure; Battista [9]
used TTS in profound SSHL without improvement of
threshold; Kakehata et al. [10] founded the same efficacy
between TTS and intravenous steroid administration.
Based on mentioned reports, although with contrasting
results, we think that TTS have promising potentiality, but
requires some further verification, taking in account that
the majority of the data are favorable with the use of TTS.
The aim of this study was to verify the efficacy and the
safety of transtympanic dexamethasone to treat SSHL patients
as first and single drug method. Considering ethical implica-
tion of performing a mininvasive procedure on middle ear, we
matched such proposed treatment with systemic prednisone
administration that represents the widest adopted protocol.
Materials and methods
A randomized prospective study was conducted on patients
affected by idiopathic SSHL who referred to the depart-
ment from January 2008 to December 2009. The inclusion
criterion was a SSHL of at least 30 dB across three con-
tiguous frequencies over a period of 24 h. Patients with the
following characteristic were excluded: previous episode
of hearing loss, history of ear pathology, previous treat-
ments administered elsewhere, and contraindication to sys-
temic steroid administration. The patient evaluation included:
thorough history, otoscopy, bedside peripheral vestibular
system examination, pure tone audiometry (repeated weekly),
and MRI of internal auditory canal and cerebello-pontine
angle. History detailed: onset of hearing loss, otological
symptoms related with hearing loss, drugs consumed in the
past few days, and presence of others systemic diseases. The
bedside examination was done by spontaneous and positional
nystagmus, Romberg test, Unterberger test, Halmagyi test,
and Head shaking test.
The patients were randomly divided in two groups
according to treatment: Group A received transtympanic
steroid injections; Group B received oral administration of
steroids.
Transtympanic injection was done in supine position
with the head rotated to 45 to the unaffected side. Under
microscope, a myringotomy was done in the anterior-
inferior quadrant of the tympanic membrane in order to
allow the exit of the air in the middle ear during drug
injection. A solution of Dexamethasone 4 mg/ml was then
injected through the posterior-inferior quadrant completely
filling the middle ear. The patient maintained the position
of the head for 20 min and was instructed to avoid swal-
lowing, speaking, and movements of the head. The trans-
tympanic injection was repeated weekly for a total of four
injections.
The patients of Group B received an oral steroid treat-
ment with 60 mg of Prednisone tapered over 14 days.
An audiogram was done weekly during the treatment
protocols in both the groups.
The follow-up in the following 6 months included an
audiogram every month.
Patients lost during the follow-up and with evidence of
retrocochlear disease at MRI (i.e., vestibular schwannoma)
were excluded from the analysis.
The criterion adopted in this study to assess a thera-
peutic effect was an improvement of 10 dB on PTA. This
criterion was the widest adopted in the recent analysis on
argument published in English literature [11–17].
All data were entered in a database created within
EpiInfo 3.5.1 software. Absolute and relative frequencies
were calculated for qualitative variables, while quantitative
variables were summarized as mean ± standard deviation.
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Continuous data were compared with the Student’s t test
and one-way ANOVA. The two-tailed significance level
chosen for all analysis was 0.05. The data were analyzed
using R statistical software package [R Development Core
Team. R statistical software package, version 2.2.0, 2005.
Available at: www.r-project.org].
All patients signed an informed consent before the
treatment and the Institutional Review Board approved this
study.
Results
Among 51 patients affected by idiopathic SSHL, we
evaluated 46 patients that completed the protocol. Three
patients were lost during the treatment and two patients had
evidence of vestibular schwannoma at MRI.
25 patients (54.3%) were treated with transtympanic
therapy whereas 21 (45.7%) underwent systemic treatment.
The mean age of the whole series was 50 years (47 for
group A and 54 for group B). The mean time of presen-
tation after onset of symptoms was 6.8 days; the group A
had a mean delay of starting treatment of 9.4 days and it
was 3.8 days for group B. Tinnitus was present in 36
(78.2%) patients: 19 (76%) in group A and 17 (81%) in
group B. Dizziness was always associated with tinnitus and
was present in 13 (28.2%) of cases, equally distributed in
two groups. The mean of initial PTA was 59 dB for the
whole series: 65 dB for group A and 51 dB for group B.
An improvement better than 10 dB was obtained in 20
(80%) patients of group A and in 17 (81%) patients of
group B, with a total of 37 patients (80.5%). The mean
relative gain in PTA was 41.16% in the group A and 44.7%
in the group B. Worsening of hearing was recorded in one
patient of group B during treatment who did not show any
recovery. No complications related to the treatment were
noted in both the groups.
Table 1 summarizes the baseline characteristics of the
46 patients studied.
The anagraphic and clinical baseline factors involved in
PTA improvements in groups with transtympanic steroid
and systemic treatments are summarized in Table 2. In
both groups, mean improvements were higher but not sta-
tistically significant in patients aged 39–59 years, in males,
in subjects without vertigo and tinnitus and in patients
treated after 3–10 days of onset. Although not statistically
significant, subjects with left ear hearing loss had a higher
improvement in the group treated with transtympanic
therapy and had a lower improvement in the group treated
with systemic therapy.
A comparison between transtympanic and systemic
treatments is shown in Fig. 1. In the frequencies tes-
ted (0.5, 1, 2, and 4 kHz), PTA improvements after
transtympanic treatment were higher than after systemic
treatment, but these differences were not statistically sig-
nificant (P = 0.61).
Finally, the Fig. 2 shows that both transtympanic and
systemic treatment had similar clinical recovery times
(15.9 and 21.1 days, respectively; P = 0.63).
Discussion
The use of transtympanic steroid is a known procedure.
Itoh and Sakata [18] first reported its use in 1991 in
treatment of patients with Meniere’s disease. The first use
of transtympanic therapy in SSHL was described by
Silverstein et al. [12].
The value of systemic therapy with steroids was proved
in several reports [3, 4, 15, 19–21], even if other authors
did not find any improvement in patients after its use [1, 2,
6]. The TTS therapy emerged in the recent years as a
promising treatment as salvage therapy after systemic
treatment failure [7, 8, 22–24]. If systemic steroid is the
most accepted treatment and the TTS was used as salvage
treatment, why not use it as the first line therapy?
The rationale supporting the TTS administration is the
round window membrane permeability to the drugs. Ele-
vated perilymphatic concentration of steroids can be
achieved after transtympanic administration, higher than
Table 1 Baseline characteristics of patients with sudden loss hearing
(N = 46)
N %
Age
\39 years 12 26.1
39–59 years 19 41.3
[59 years 15 32.6
Sex
Male 28 60.9
Female 18 39.1
Ear
Left 26 56.5
Right 20 43.5
Vertigo
Yes 13 28.3
No 33 71.7
Tinnitus
Yes 36 78.3
No 10 21.7
Days before beginning treatment
\3 15 32.6
3–10 23 50
[10 8 17.4
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after systemic administration [25, 26]. The distribution of
drugs shows a decreasing concentration from basal turn of
the cochlea to the apical portion, with maximum level near
the inner aspect of the round window membrane. The
diffusion of molecules into inner ear fluids and
compartments follows different pathways: with perilym-
phatic flow through the helicotrema (longitudinal) and
across the spiral ligament (interscalar communication). Salt
et al. [27] found that whatever protocol adopted did not
influence the relative distribution of drugs into inner ear
fluids, believing that this fact is secondary to the drug
clearance from the perilymph. However, the cochlear
pharmacokinetics is not clearly understood and the distri-
bution of drugs along the human cochlea is different than
that of rodents used for the study and in the opinion of
Mikulec et al. [28], it is not a good model.
The more diffuse transtympanic steroids administration
protocols are three as: primary and exclusively treatment,
adjunctive therapy to the standard procedure adopted (i.e.,
systemic steroids), and salvage therapy after failure of
systemic one. In this study, we report only the results of the
first line TTS therapy against the old protocol with sys-
temic steroid therapy, but we adopted the TTS also as
salvage therapy after systemic treatment failure.
There are many advantages of TTS use. The primary, in
the authors’ opinion, is the possibility to treat all patients
presenting with SSHL avoiding systemic effects of steroids
and thus treating those patients in which systemic steroids
are contraindicated (i.e., immunocompromised patients,
diabetics, tuberculosis, HIV). High dose regimen of ste-
roids may expose patients (elder ones in particular) to
various adverse effects: glucose intolerance, avascular
necrosis of the hip, insomnia, irritability, gastritis, and
osteoporosis. Other advantages are: it is an office-based
procedure, reduction in delay of start of treatment after
diagnosis and to treat only the affected side and the pos-
sibility to combine TTS with other systemic drugs without
dangerous pharmacological interactions.
However, there are some drawbacks of TTS: residual
tympanic perforation, pain during and after treatment,
infection, vertigo (usually temporary), and dysgeusia.
Hearing loss has been reported following an injection of
steroid.
Table 2 Factors involved in PTA improvement (difference between
baseline PTA and recovered PTA) in patients after transtympanic and
systemic treatment
Mean PTA improvement dB ± SD
Transtympanic
treatment
P value Systemic
treatment
P value
Age
\39 years 26.1 ± 22.5 8.3 ± 20.2
39–59 years 29.4 ± 20.6 0.88 28.1 ± 9.6 0.08
[59 years 24.2 ± 18.8 19 ± 12.6
Sex
Male 25.7 ± 14.7 0.61 22.2 ± 16.3 0.66
Female 30.3 ± 22.6 19.5 ± 11.1
Ear
Left 28.2 ± 18.7 0.76 19.5 ± 16.3 0.63
Right 25.6 ± 23.3 22.5 ± 11.1
Vertigo
Yes 17.1 ± 16.4 0.12 19.2 ± 9.7 0.72
No 31.1 ± 20.6 21.7 ± 15.4
Tinnitus
Yes 24.6 ± 22.4 0.27 20.6 ± 14.9 0.81
No 35.2 ± 6.5 22.5 ± 9.6
Days before treatment
\3 10 ± 14.1 18.5 ± 15.5
3–10 32.6 ± 22.2 0.17 25.7 ± 11 0.55
[10 19.8 ± 11.1 20 ± 0
PTA pure tone average
Fig. 1 PTA improvement (difference between baseline PTA and
recovered PTA) at different frequencies (0.5, 1, 2, and 4 kHz) and at
all four frequencies in patients treated with transtympanic and
systemic therapy
Fig. 2 Recovery time of patients after transtympanic and systemic
treatment
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To deliver dexamethasone into middle ear cleft many
techniques are proposed: direct injection, delivery through
a myringotomy with a tube, delivery with a wick placed on
the round window through a myringotomy, and drug
infusion by an implantable pump device. We preferred the
direct transtympanic needle injection after an anterior-
inferior needle myringotomy, but if patient requires a short
treatment protocol, a 1-day protocol may be done placing a
tube to permit several injections in a short period of time
(24 h) [29]. The implantation of device into middle ear is
not comfortable for the patients and did not show any
additional benefits. Furthermore the concept of air evacu-
ation is useful to permit a complete filling of the middle ear
and thus maximum drug loading is possible. The amount of
solution injected into middle ear varies between 0.3 and
0.6 ml. We tried to uniformly inject 0.4–0.5 ml of solution
to avoid drug exposure discrepancies between the patients.
We adopted a weekly dose for a total of four injections
in all the patients. Notwithstanding that the greater part of
hearing recovery occurred after the first two injections, the
treatment was not suspended, for the reason that we believe
that restoring the ionic equilibrium inside cochlear fluids
leads to stabilization of the hearing recovery.
The definition of the true therapeutic intervention on
hearing improvement is difficult to determine because of
the natural history of SSHL includes a high rate of spon-
taneous recovery ranging from 31 to 65% [2, 3, 6]. How-
ever, the results presented in this study confirm the efficacy
of TTS as first line treatment of patients with SSHL. The
recovery rate was analogous between systemic steroids and
TTS with a response in about 80% of patients; the obtained
improvement rate was better than that expected with simple
observation, which can reach 65% [2, 3, 6]. The high
recovery rate obtained and the similar results between TTS
and systemic therapy justify the adoption of such treatment
modality as first choice in the department.
The difference between onset of hearing loss and start of
the treatment that is present between the two groups was
casually determined by randomization. It may be appar-
ently a limitation of the study, but, on the contrary, could
be a supporting point in favor of TTS use.
As showed in the series, the outcome was not related to
the time of treatment after the hearing loss. This was also
noted by Parnes et al. [25] treating 37 patients affected by
several inner ear disorders and by Ho et al. [22] in 39 cases.
The absence of relationship between start of treatment and
outcome is very important to modify the prevalent notion
to consider SSHL as an emergency, allowing the option to
perform thorough examination including MRI, conse-
quently avoiding wrong diagnoses. In the study, the two
groups had a casual difference of start of treatment time
(about 9 days in transtympanic treatment and about 4 days
in systemic treatment). This could be apparently a
limitation for the analysis, but observing the outcome
obtained, the TTS has a possible role as programmable
treatment, maintaining the same efficacy of promptly
administered steroids. However, reading the results, the
delay of treatment have to be intended as a window of
10 days in which the treatment may start after a proper
diagnostic itinerary.
Conclusions
The treatment of SSHL remains a challenge for the otol-
ogists. This prospective randomized clinical study showed
good result in terms of hearing recovery similar to the
outcome of the systemic therapy and better than the
expected results of the simple observation without treat-
ment. The statistical analysis confirmed the equal results
between systemic therapy with steroid and TTS; conse-
quently we can consider TTS as a first line treatment,
reducing possible side effects of systemic drug adminis-
tration. Interesting information emerged about the treat-
ment timing, as supported by results; the delay of treatment
does not influence the outcome, allowing treating patients
even after 10 days of onset. The TTS requires further
verification and prospective study to improve the outcome:
determination of the better interval between dosages and
determination of the most useful dosage.
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